To Abreviate or not to Abreviate [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2010-04-24 10:16 (5909 d 20:26 ago) – Posting: # 5210
Views: 18,638

Dear KR,

sorry if I contributed to the obfuscation of your thread.
I read briefly through the document from the OGD and it does confuse me somewhat.
As far as I can tell, this calls for an assessment of relative potency via a rudimentary dose-response curve and bootstrap. Validating a stats package for the botstrap is one hurdle in itself.

But, actually, in order to assess relative potency I would believe that something more complex than a three-arm study would be needed, so I cannot tell you exactly which groups to have. I cannot tell if the FDA wants to see just the dose-response for Ref and then a single point of Test. If they will accept it, it would to me seem to be three arms and should be easy, but does the Emax model given in the document really allow for that?

Best regards
EM.

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
351 visitors (0 registered, 351 guests [including 21 identified bots]).
Forum time: 06:42 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5